Shares of Ocugen have shed more than half their value since hitting a 52-week high of €2.35 in March, but the company’s chief financial officer has just put her own cash on the line. Rita Johnson-Greene purchased 21,000 Ocugen shares on the open market in June for roughly $26,000, a move analysts often interpret as a vote of confidence from management at a critical inflection point.
The timing is no accident. The BIO International Convention kicked off this week in San Diego, and Ocugen’s CEO, Dr. Shankar Musunuri, is using the event to showcase the company’s gene therapy platform — a venue that doubles as a hub for forging potential commercial partnerships. The CFO’s purchase, coming just ahead of that conference, suggests the corner office sees value where the broader market sees only uncertainty.
Three Programs, One Pivotal Quarter
Ocugen’s most advanced asset, OCU400, is a gene therapy for retinitis pigmentosa that works independently of the underlying mutation, giving it a broader potential patient population than rival approaches. The company has now enrolled all 140 patients in its Phase 3 trial and plans to submit a rolling biologics license application in the third quarter. If the regulatory process moves smoothly, the treatment could reach the market next year.
That filing is not the only milestone on the horizon. Two other programs are approaching key data points:
- OCU410: A pivotal efficacy study for dry age-related macular degeneration is set to begin in the third quarter.
- OCU410ST: An interim analysis for the Stargardt disease program is expected this summer.
These three programs, each targeting retinal diseases with high unmet need, form the backbone of Ocugen’s valuation story. The company secured its financial runway earlier this spring through a $130 million convertible note offering, which should fund the intensive clinical calendar through the end of the year and into the planned BLA submission.
Should investors sell immediately? Or is it worth buying Ocugen?
A Stock Drifting While the Sector Warms Up
Despite the insider buy and the packed pipeline timeline, Ocugen’s stock has been listless. At €1.12, the shares trade roughly 11% below their 50-day moving average and 15% below the 200-day moving average — a configuration that typically signals fading momentum. The relative strength index sits at 46.7, squarely neutral territory. The market is drifting, not panicking and not charging.
The broader biotech landscape, meanwhile, has brightened. AbbVie’s reported interest in Apogee Therapeutics for roughly $11 billion sent that stock surging more than 55% premarket. Aurobindo Pharma secured clearance for a $250 million acquisition. Capital is flowing back into pharmaceutical names. Ocugen has tagged along only modestly, gaining about 7% over the past week and 33% year-to-date, even though the stock is still down roughly 5% on a calendar-year basis.
The Federal Reserve’s decision to hold rates steady between 3.50% and 3.75% has at least removed the risk of rising capital costs for pre-revenue biotechs. But lower rates alone don’t create catalysts.
Asymmetry on Paper, Binary in Reality
Analysts see a price target of €9.96, implying a 777% upside from current levels. That number reflects the potential of a successful pipeline, not the weighted probability of each trial. In early-stage biotech, large disparities between current price and targets are not unusual — Ocular Therapeutix, a competitor in the ophthalmology space, is targeting an NDA filing for its macular degeneration candidate in the fourth quarter of 2026. Such regulatory milestones can rewrite market caps overnight.
Ocugen’s annualized volatility of 43% captures the market’s inability to price in the outcome. The insider purchase adds a layer of management conviction, but the stock’s descent from its March high shows how quickly expectations can shift when milestones are still months away. For now, Ocugen remains a promise without a date — but this summer’s calendar could finally provide one.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from June 22 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 22.
Ocugen: Buy or sell? Read more here...
